LOGIN

International Epidemiology Databases to Evaluate AIDS

Home >> Publications >> Differences in lipid measurements by antiretroviral regimen exposure in cohorts from Asia and Australia.

Publication

Author(s):

Achhra AC, Amin J, Hoy J, Tanuma J, Sirisanthana T, Nolan D, Merati T, Giles M.

Pub Title:

Differences in lipid measurements by antiretroviral regimen exposure in cohorts from Asia and Australia.

Pub Date:

May 14 2012

Pub Region(s):

Asia-Pacific

Page Number:
246280

Journal:

Title: 
AIDS Research and Treatment
Link: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3363372/

PubMed: 22675613
Pub PDF: PDF icon 22675613.pdf

Abstract
We explored the mean differences in routinely measured lipids (total cholesterol, triglycerides, and high-density lipoprotein cholesterol) according to exposure to different combination antiretroviral regimens in Asian (n = 2051) and Australian (predominantly Caucasian, n = 794) cohorts. The regimen was defined as at least 3 antiretroviral drugs with at least 2 nucleoside-reverse transcriptases (NRTIs) and either of at least one protease inhibitor (PI) or non-nucleoside-reverse transcriptases (NNRTIs). We categorised cART regimens as: NRTIs as tenofovir based or not; NNRTIs as nevirapine or efavirenz (but not both); and PI as atazanavir based or not. We found that the impact of various antiretroviral regimens on lipids in Asian and Australian cohorts was only different by cohort for total cholesterol (P for interaction between regimen and cohort: <0.001) but not in case of other lipids (P for interaction: >0.05). The differences in total cholesterol were however small and unlikely to be of clinical significance. Overall, tenofovir with nevirapine or atazanavir was associated with the most favorable lipids, while the PI regimens without tenofovir and atazanavir were associated with least favorable lipids. We conclude that the impact of various ART regimens on lipids is largely similar in Asian and Australian cohorts and that the newer drugs such as tenofovir and atazanavir are likely to provide similar benefit in terms of lipid profiles in both populations.

PMID: 22675613 [PubMed]

PMCID: PMC3363372

 
The following websites provide guidelines and policies when citing from PubMed®: http://www.ncbi.nlm.nih.gov/books/NBK7243/
http://www.nlm.nih.gov/bsd/policy/cit_format.html

Citation:

Achhra AC, Amin J, Hoy J, Tanuma J, Sirisanthana T, Nolan D, Merati T, Giles M. Differences in lipid measurements by antiretroviral regimen exposure in cohorts from Asia and australia. AIDS Res Treat. 2012;2012:246280. doi: 10.1155/2012/246280. Epub 2012 May 14. PubMed PMID: 22675613; PubMed Central PMCID: PMC3363372.